Capital Management, Llc Lux... Net Worth

Insiders trading at Genocea Biosciences Inc

Over the last 11 years, insiders at Genocea Biosciences Inc have traded over $9,875,933 worth of Genocea Biosciences Inc stock and bought 177,421,644 units worth $259,728,894 . The most active insiders traders include Forest Baskett, Scott D Sandell, eAnthony A. Jr. Florence. On average, Genocea Biosciences Inc executives and independent directors trade stock every 27 days with the average trade being worth of $0. The most recent stock trade was executed by Diantha Duvall on 2 June 2022, trading 1,355 units of GNCA stock currently worth $81.

What does Genocea Biosciences Inc do?

Genocea's mission is to conquer cancer by developing personalized cancer immunotherapies in multiple tumor types. Our unique ATLAS™ platform comprehensively profiles each patient's T cell responses to potential targets, or antigens, on the tumor. ATLAS enables us to optimize the neoantigens for inclusion in our immunotherapies and exclude inhibitory antigens, Inhibigens™, that can exert an immunosuppressive effect. We are advancing two ATLAS-enabled programs: GEN-009, our neoantigen vaccine and GEN-011, our neoantigen-specific cell therapy using T cells derived from peripheral blood.

Genocea Biosciences Inc executives and stock owners

Genocea Biosciences Inc executives and other stock owners filed with the SEC include:

• William Clark,
  President, Chief Executive Officer, Director
• William D. Clark M.B.A.,
  Pres, CEO & Director
• Girish Aakalu,
  Chief Business Officer
• Thomas Davis,
  Chief Medical Officer
• Jessica Flechtner,
  Chief Scientific Officer
• Dr. Thomas A. Davis,
  Chief Medical Officer
• Dr. Girish N. Aakalu Ph.D.,
  Chief Bus. Officer
• Katrine Bosley,
  Independent Director
• Kenneth Bate,
  Independent Chairman of the Board
• George Siber,
  Independent Director
• Michael Higgins,
  Independent Director
• Ronald Cooper,
  Independent Director
• Ali Behbahani,
  Independent Director
• Gisela Schwab,
  Director
• Narinderjeet Singh,
  Senior Vice President - Pharmaceutical Sciences and Manufacturing
• Diantha Duvall,
  Chief Financial Officer
• Dr. Jessica Baker Flechtner,
  Chief Scientific Officer
• Diantha Duvall,
  CFO & Sec.
• Dr. Raymond D. Stapleton Jr.,
  Exec. VP of Pharmaceutical Sciences & Manufacturing
• Jacquelyn L. Sumer,
  Chief Legal & Compliance Officer
• Kevin Bitterman,
  Director
• Jonathan Poole,
  Chief Financial Officer
• Seth V Hetherington,
  Chief Medical Officer
• Paul Giannasca,
  VP of Development
• Stephen J Hoffman,
  Director
• Howard Mayer,
  Director
• Eric S Hoffman,
  Chief Business Officer
• Venture Management Co. V, L...,
  
• John Lunger,
  Director
• Michael Alfieri,
  Principle Financial Officer
• Derek M Meisner,
  SENIOR VP AND GENERAL COUNSEL
• Pamela Carroll,
  SVP IMMUNO-ONCOLOGY
• David M Mott,
  10% owner
• Anthony A. Jr. Florence,
  10% owner
• Scott D Sandell,
  10% owner
• Mohamad Makhzoumi,
  10% owner
• Peter W. Sonsini,
  10% owner
• Joshua Makower,
  10% owner
• Carmen Chang,
  10% owner
• Forest Baskett,
  10% owner
• Peter J Barris,
  10% owner
• Enterprise Associates 16, L...,
  
• Jacquelyn L Sumer,
  CHIEF LEGAL & COMPLIANCE OFF
• Robert E Jr Farrell,
  VP of Finance & Administration
• Venture Management Co. V, L...,
  
• Capital Management, Llc Lux...,
  
• Simeon George,
  Director
• & Johnson Johnson & Johnson...,
  
• Plc Gsk,
  10% owner
• Paul Edward Walker,
  10% owner
• Jennifer Lyn Herron,
  Director
• Raymond D Jr Stapleton,
  CHIEF TECHNOLOGY OFFICER